

Lil Bianchi appointed Non-Executive Chair of PainChek

- Lil Bianchi appointed to Chair PainChek effective immediately
- Ms Bianchi is a highly experienced Chair and NED, guiding successful medtech companies through growth inflection points and international expansion, including 4DMedical (ASX:4DX) and Qscan Radiology Group
- This appointment supports PainChek's business development drive in the US market following FDA De Novo clearance and access to US CMS reimbursement
- John Murray transitions to Non-Executive Director role

Sydney, Australia, 25 May 2026: PainChek Ltd (ASX: PCK), developer of the world's first AI-powered pain assessment and monitoring application, is pleased to announce the appointment of Ms Lil Bianchi as Non-Executive Chair of the Board, effective today. Ms Bianchi succeeds Mr John Murray, who has transitioned to Non-Executive Director.

Ms Bianchi brings a proven track record of guiding medical technology companies as they navigate growth inflection points and accelerate global market adoption including the US and Europe. With deep expertise spanning business transformation, AI and SaaS technologies, governance and capital markets, she has helped lead companies through expansion, commercialisation and international growth.

Her experience across global corporates, tech start-ups and IPO environments positions her to guide companies in scaling innovative medical technologies into major healthcare markets. Combining board, CEO and senior executive leadership experience with a strong background in strategy, risk and digital disruption, Ms Bianchi has a demonstrated ability to help companies convert breakthrough technology into commercial traction and long-term shareholder value.

Ms Bianchi is Chair of medtech company 4DMedical (ASX:4DX), a global leader in respiratory imaging that has grown from IPO in 2020 to a \$2b+ market capitalisation and entry to the ASX200 in 2026. During this period 4DMedical has achieved major regulatory clearances globally and grown its customer base in USA to include some of the world's most renowned medical institutions.

Ms Bianchi is also a Non-Executive Director of Qscan Radiology Group. Founded in 2006, Qscan has grown to more than 80 clinics focused on diagnostic medical imaging and interventional procedures across five Australian states.

Incoming Chair, Ms Lil Bianchi, commented:

"I am absolutely delighted to be appointed Chair of PainChek at this exciting moment in the Company's journey. PainChek is well positioned as the world's first FDA-cleared medical device for pain assessment. I look forward to joining the team and bringing my additional experience and capability to support PainChek's global expansion at this key inflection point,

as we accelerate access into the large US market with our groundbreaking medical device that has immediate access to US CMS reimbursement.

I want to take this opportunity to thank John Murray, who has Chaired the Company through listing on the ASX, development of a first commercial product and establishment in the Australian, UK and North American markets."

Mr John Murray commented:

"After an extensive search, we are delighted to be able to announce the appointment of someone of the calibre of Lil Bianchi to Chair the Company for the next stage of its international growth. Lil has excellent skills and proven experience of growing medtech in international markets, and in particular penetrating the North American market. I look forward to working with Lil as a Non-Executive Director"

This announcement has been approved for release by the Board.

For more information:

Natalie Climo
Company Secretary, PainChek
natalie.climo@boardroomlimited.com.au
02 8016 2875

About PainChek

[PainChek®](#) is the world's first regulatory-cleared medical device for the assessment of pain, enabling best-practice pain management for people living with pain in any environment, from those who cannot reliably self-report their pain, those who can, and for those whose ability to self-report their pain fluctuates.

The PainChek® app is available on smartphones and tablets and combines PainChek's AI pain assessment tool, which intelligently automates the multidimensional pain assessment process, with the Numerical Rating Scale (NRS). This hybrid functionality allows accurate, consistent pain assessment at the point of care, and for care to be considered in PainChek's detailed reporting suite, PainChek® Analytics.

Globally, PainChek® has attained regulatory clearance as a medical device in Australia, Canada, the European Union, New Zealand, Singapore, Malaysia, the United Kingdom and most recently FDA De Novo clearance in the United States.

PainChek® has contracts with over 2,000 aged care facilities, with more than 20,000,000 digital pain assessments conducted to date, and is trusted by thousands of nurses, carers, and clinicians.

PainChek® is setting a new benchmark for pain assessment. Being the first TGA-approved and FDA-cleared medical device for pain assessment, PainChek® combines AI and Human Intelligence to detect pain in people who cannot reliably self-report.

With over 20 million assessments completed globally, PainChek hosts the richest pain dataset, which is redefining how care teams understand, assess and manage pain. The technology is clinically backed and enables evidence-based pain assessment at the point of care, allowing for faster intervention and better outcomes.

Actionable insights can be derived from PainChek's real time dashboards and comprehensive reporting structures, ensuring quality, transparency and accountability at all levels; from RNs to Executives and Boards. PainChek® is leading the Future of Pain Assessment - Today.

Using PainChek®, facilities can:

- Ensure greater consistency, continuity, and diagnostic certainty in pain assessment and management by decreasing subjectivity and removing unintentional assessor bias

ASX ANNOUNCEMENT

25 May 2026



- Streamline the pain assessment process for time-poor carers, with access to the PainChek® tool, the NRS, pain trends, and charting in one solution
- Simplify record-keeping and documentation to demonstrate compliance and support funding claims, with all historical pain assessment data in one place
- Enhance engagement with GPs and allied healthcare professionals

Clinical studies conducted in Australian and UK residential aged care have been published in various peer-reviewed journals including the [Journal of Alzheimer's Disease](#). An article in [BMC Geriatrics](#) indicates that PainChek® is a valid and reliable instrument to assess the presence and severity of pain in people with moderate-to-severe dementia living in aged care. Further information on clinical studies can be found [here](#). PainChek® has successfully supported accurate pain assessment and management for thousands of adults worldwide living with dementia, disability, or other conditions impacting their ability to self-report pain. Building on the success of this technology, the clinically validated [PainChek® Infant app](#) identifies and detects six facial action units indicative of pain in infants aged one month to 12 months.

The need for PainChek as a best-practice pain management solution also extends to older people living at home and with access to home care packages that enable long-term home living. PainChek is expanding into home care by partnering with home care and disability service providers.

For more information, visit: <https://painchek.com>